Heartflow (HTFL) risk factors, FY2025 10-K

Risks Related to Our Business and Industry

1. 01We have incurred significant net losses since our inception, we expect to incur additional substantial losses in the foreseeable future and we may not be able to achieve or sustain profitability
2. 02product offerings or continue our operations. A decline in the value of our company could cause you to lose all or part of your investment
3. 03If healthcare providers are unwilling to change their standard practice regarding the evaluation of CAD, our business, financial condition, results of operations and prospects will be adversely affected
4. 04We face risks associated with a concentrated customer base
5. 05The size and expected growth of our addressable market may be smaller than we estimate
6. 06We may not be successful in updating or otherwise enhancing the Heartflow Platform
7. 07The commercialization of Heartflow Plaque Analysis is nascent, and we may not be able to achieve or maintain sufficient market acceptance or the levels of utilization we expect from Heartflow Plaque Analysis or any other future product
8. 08We face risks associated with our use and development of AI models, which may result in operational challenges, legal liability, reputational concerns and competitive risks
9. 09Our Heartflow Platform and the data and models it generates could have bugs, defects or errors, including human quality control errors, or otherwise fail to meet the expectations of patients, physicians and third-party payors, which could adversely affect our reputation, business and operating results
10. 10We depend on our talent to grow and operate our business, and if we are unable to hire, integrate, develop, motivate and retain our personnel, including highly qualified, technical personnel, we may not be able to grow effectively and this could adversely affect our business
11. 11If we fail to properly manage our future growth, our business could suffer
12. 12Our business could be disrupted by catastrophic events
13. 13disaster recovery arrangements and insurance coverage, the ability of our customers to access and utilize our Heartflow Platform could be interrupted, or we could lose critical data, which would have a negative impact on our business
14. 14Consolidation among healthcare providers could have an adverse effect on our business, financial condition, results of operations and prospects
15. 15We may acquire other companies, solutions or technologies, which could divert our management’s attention, result in additional dilution to our stockholders and otherwise disrupt our operations and adversely affect our operating results
16. 16Sales to customers outside the United States or with international operations expose us to risks inherent in international sales
17. 17If we do not obtain and maintain international regulatory registrations, clearances or approvals for our Heartflow Platform, we will be unable to market and sell our products outside of the United States

Risks Related to Data Privacy and Information Technology

1. 18Failure to comply with laws and regulations affecting the transmission, security and privacy of personal information (including health information) could result in significant penalties
2. 19We depend on our information technology systems, and any failure of these systems could harm our business and adversely affect our business and operating results
3. 20We rely upon AWS to operate our cloud offering; any disruption of or interference with our use of AWS would adversely affect our business, results of operations and financial condition
4. 21If we fail to offer high quality customer support, our business and reputation could suffer
5. 22Our networks and those of our third-party service providers may become the target of bad actors or security breaches that we cannot anticipate or successfully defend, which could have an adverse impact on our business

Risks Related to Legal and Regulatory Matters

1. 23We face extensive regulatory requirements to bring our products to market, and our failure to receive and maintain regulatory clearances or approvals of our current and future products in the United States or abroad or to comply with medical device regulatory requirements could adversely affect our business
2. 24Healthcare policy changes, including recently enacted legislation reforming the U.S. healthcare system could have an adverse effect on our business, financial condition, results of operations and prospects
3. 25We are subject to many laws and governmental regulations affecting our marketed products, both domestically and internationally, and any adverse regulatory action may adversely affect our business, financial condition, results of operations and prospects
4. 26Delays in the commencement or completion of future or ongoing clinical testing could result in increased costs to us and delay our ability to market the Heartflow Platform for additional indications
5. 27Interim, “top-line” and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
6. 28We may face product liability claims that could result in costly litigation and significant liabilities. We may not be able to maintain adequate product liability insurance
7. 29The Heartflow Platform may be subject to recalls, which could be costly and could harm our reputation and business
8. 30Off-label or other unlawful promotion of our products could result in costly investigations and sanctions from the FDA and other regulatory bodies
9. 31Violations of these laws and regulations may result in significant criminal and/or civil fines and penalties, as well as potential exclusion from participation in federal health care programs, that could significantly impact our business and operations
10. 32We also are subject to foreign fraud and abuse laws and regulations, which vary by country, and can prohibit many of the same activities addressed by U.S. laws
11. 33We are subject to U.S. and foreign anti-corruption and anti-money laundering laws with respect to our operations and non-compliance with such laws can subject us to criminal and/or civil liability and harm our business
12. 34We are subject to governmental export and import controls that could impair our ability to compete in international markets due to licensing requirements and subject us to liability if we are not in compliance with applicable laws
13. 35Any future litigation against us could be costly and time-consuming to defend

Risks Related to Our Intellectual Property

1. 36For information about risks related to our inability to protect our intellectual property rights outside the United States, see the risk factor titled “We may not be able to adequately protect our intellectual property rights throughout the world” below
2. 37If we are unable to protect the disclosure and use of our confidential information and trade secrets, the value of our products and technologies and our business and competitive position could be harmed
3. 38Reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed to others
4. 39Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements
5. 40Changes in patent law, precedents and policies in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products
6. 41of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i) file any patent application related to our products or (ii) invent any of the inventions claimed in our or our licensors’ patents or patent applications
7. 42We may not be able to adequately protect our intellectual property rights throughout the world
8. 43We may be involved in lawsuits to protect or enforce our patents or other intellectual property, or the patents of our licensors, which could be expensive, time consuming and unsuccessful
9. 44We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property rights or alleging that we have violated the intellectual property rights or other proprietary rights of third parties
10. 45An unfavorable outcome for any such claim could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms
11. 46The terms of our patents may not be sufficiently long to effectively protect our products and business
12. 47If we do not obtain additional protection under the Hatch-Waxman Amendments or similar foreign legislation, our business may be materially affected
13. 48Open-source software licenses often impose unanticipated or unclear restrictions on us or could expose us to litigation, and using open-source software has inherent risks, any of which could impair our ability to successfully commercialize the Heartflow Platform
14. 49Intellectual property rights do not necessarily address all potential threats to our competitive advantage

Risks Related to Financing and Tax Matters

1. 50We may require additional capital to support business growth, and this capital might not be available on terms favorable to us, or at all, and may dilute ownership of our common stock for our stockholders
2. 51Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide
3. 52We are subject to risks associated with currency fluctuations, and changes in foreign currency exchange rates could impact our results of operations
4. 53Our ability to use our net operating losses and tax credits to offset future taxable income and taxes may be subject to certain limitations
5. 54Our international operations subject us to potentially adverse tax consequences
6. 55Our effective tax rate may vary significantly from period to period
7. 56Taxing authorities may successfully assert that we should have collected or in the future should collect sales and use, value added or similar taxes, and we could be subject to tax liabilities with respect to past or future sales, which could adversely affect our results of operations

Risks Related to Our Common Stock

1. 57There may not be a sustainable trading market for our common stock
2. 58The market price of our common stock may be volatile, which could cause the value of your investment to decline and could result in substantial losses for investors
3. 59We are an emerging growth company, and the reduced reporting requirements applicable to emerging growth companies could make our common stock less attractive to investors
4. 60We incur increased costs and are subject to additional regulations and requirements as a result of becoming a public company, which could lower our profits or make it more difficult to run our business
5. 61If we are unable to design, implement and maintain effective internal control over financial reporting in the future, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock may decline
6. 62Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
7. 63Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval
8. 64We have broad discretion in the use of net proceeds to us from our IPO and may not use them effectively
9. 65We do not intend to pay dividends in the foreseeable future. As a result, your ability to achieve a return on your investment will depend on appreciation in the market price of our common stock
10. 66If our operating and financial performance in any given period does not meet any guidance that we provide to the public, the market price of our common stock may decline
11. 67If securities or industry analysts issue an adverse or misleading opinion regarding our stock, or if they cease coverage of us or fail to publish reports on us regularly, our stock price and trading volume could decline
12. 68We may be subject to securities litigation, which is expensive and could divert management attention
13. 69Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management